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osting by EAbstract Hypertension has a serious harmful effect on the physiological and biochemical func-
tions of heart that end with the appearance of cardio-vascular diseases. Asymmetric dimethylargi-
nine (ADMA) has evolved as an important regulator of nitric oxide (NO) synthesis. The
relationship between ADMA and essential hypertension has been scarcely explored. This study is
aiming to investigate the physiological, pathological, and biochemical roles of plasma ADMA in
relation to serum nitric oxide and also the relation between ADMA and NO with other traditional
cardiovascular risk factors in hypertensive patients.
Methods: The study was designed as a prospective case-control study which included 60 hyperten-
sive cardiovascular patients and 10 healthy volunteers as a control group. The patients were divided
into four groups: hypertension with cardiovascular complications, uncontrolled hypertension
(blood pressure >139/89), controlled hypertension, and control group. Levels of ADMA and nitric
oxide were assessed and statistically correlated to other clinical and laboratory values [cholesterol,
triglycerides, urea, creatinine, and fasting and postprandial blood sugar].
Results: The plasma ADMA level in group I was signiﬁcantly increased (2.29 ± 0.06 lmol/L) com-
pared to control group (0.55 ± 0.05 lmol/L) P= 0.001 and also serum NO level was signiﬁcantly
decreased in this group (11.65 ± 0.75 lmol/L) compared to control group (52.11 ± 1.43 lmol/L)
P= 0.001. This group had variable complications, e.g., ischemic heart disease, pulmonary hyperten-itical Care Medicine Depart-
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118 O. Tayeh et al.sion, pulmonary embolism, and cerebrovascular disease. Group II: plasma ADMA level was signif-
icantly increased in this group (1.41 ± 0.06) and also serum NO level was signiﬁcantly decreased
(30.91 ± 1.31) compared to control group (P= 0.001). Group III: they had a lower plasma level
of ADMA (1.11 ± 0.05) compared to groups I and II (P value: 0.001) and signiﬁcantly higher than
the control group. The serum NO level was signiﬁcantly decreased (40.01 ± 0.67) compared to con-
trol group and signiﬁcantly higher than groups I and II. Hypertensive groups I, II, and III showed a
signiﬁcant increase in mean fasting and postprandial blood sugar (171.4 ± 71.00, 143.64 ± 37.00,
and 137.00 ± 27.06 mg/dl, respectively) compared to control group (85.32 ± 13.17 mg/dl). Urea,
creatinine, cholesterol, and triglycerides in the hypertensive groups (I, II, and III) showed a signiﬁcant
increase compared to control group with signiﬁcant positive correlation in relation to ADMA.
Conclusions: ADMA is elevated in hypertensive patients. Elevated ADMA concentrations are asso-
ciated with impaired endothelium functions, which are demonstrated by NO reduction in the sera of
hypertensive patients. ADMA is correlated positively with the traditional cardiovascular risk factors.
Also there was a strong signiﬁcant negative correlation between NO and ADMA levels in the whole
hypertensive groups.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hypertension has a serious harmful effect on the physiological
and biochemical functions of heart that ended with the appear-
ance of cardio-vascular diseases. Endothelium-mediated regu-
lation of vascular tone and vascular structure has been a
fascinating topic in cardiovascular medicine since the ﬁrst
discovery in 1980 by Furchgott,1,2 who stated that the vascular
relaxation in response to acetylcholine critically depends upon
the presence of an intact vascular endothelium. Nitric oxide
(NO) was discriminated to be an elusive mediator (previously
named endothelium-derived relaxing factor and released by
healthy endothelium) that causes vascular dilatation, which
synthesized within the endothelium from amino acid L-arginine
by enzyme nitric oxide synthetase.3
Endothelial dysfunction occurs whenever the biological
functions of NO are impaired, be it at the level of NO gener-
ation, during its diffusion from endothelial cells to its target
cells in the subendothelial layers of the vascular wall or to
the cells of the ﬂowing blood, or within the subsequent signal-
ing cascade that links NO to its cellular functions, have all
been shown to be involved in the phenomenon called endothe-
lial dysfunction under varying conditions.4
Asymmetric dimethylarginine (ADMA) has evolved as an
important regulator of NO synthesis in recent years. ADMA
is an endogenous inhibitor of NO synthetase. Several cell types
including human endothelial and tubular cells are capable of
synthesizing andmetabolizing ADMA. Also it is formed during
proteolysis of methylated proteins and removed by renal excre-
tion or metabolic degradation by the enzyme dimethylarginine
dimethyl-aminohydrolase (DDAH) to L-citrulline and dimeth-
ylamine. Elevated levels of ADMA have been reported in many
conditions to be associated with a high cardiovascular risk.5
The relationship between ADMA and essential hyperten-
sion has been scarcely explored. Plasma ADMA levels was
measured and coherently found to be higher in hypertensive
patients,6,7 than in normotensive healthy subjects,8 particularly
in salt-sensitive individuals.9 However, in none of these studies
the relationship between ADMA and endothelial function was
tested. In one study, urinary nitrate excretion was reduced con-
comitantly with elevated ADMA plasma levels in patients with
essential hypertension, suggesting that systemic NO produc-
tion was impaired in these patients.7This study is aiming to investigate the physiological, path-
ological, and biochemical roles of plasma ADMA in relation
to serum nitric oxide and also the relation between ADMA
and NO with other traditional cardiovascular risk factors in
hypertensive cardiovascular patients.
2. Patients and methods
After local ethics committee approval and a written consent
the study was conducted as a prospective case-control study
which included 60 consecutive hypertensive cardiovascular
patients, who were admitted to Critical Care Department of
Cairo University and 10 volunteers as control. Our study pop-
ulation has been categorized into four groups: group I con-
sisted of twenty hypertensive patients with cardiovascular
complications. Group II had 20 patients with uncontrolled
hypertension with or without treatment and there were no car-
diovascular complications. Group III, which had 20 patients
with controlled hypertension deﬁned as blood pressure below
139/89,10 who had a regular anti hypertensive drugs. Fourth
group consisted of 10 volunteers as control.
The following data were obtained: history analysis and clin-
ical examination, then blood samples were collected from all
patients. A part of blood samples collected on heparin to eval-
uate ADMA, the remaining samples were collected without
anticoagulant and separated sera were stored at 4 C pending
various biochemical assays.
1. Determination of serum nitric oxide level: was esti-
mated in serum according to Griess reaction using a
commercial kit purchased from Cayman Chemical
Company, Ann Arbor, USA.11
2. Determination of plasma asymmetric dimethylarginine
(ADMA): was determined using commercial kits pur-
chased from American Laboratory Products Company
(Alpco Diagnostics), USA and according to the
method of Schulze et al.12
Sunrise absorbance reader (TECAN) was used to determine
plasma ADMA and serum nitric oxide levels. APEL PD-303 S
spectro photometer was used to measure: total cholesterol, tri-
glycerides, urea, creatinine, and fasting and postprandial blood
sugar.
Figure 1 Correlation coefﬁcient between plasma ADMA and
blood pressure in all studied patients groups.
Asymmetric dimethylarginine as a prognostic marker for cardiovascular complications in hypertensive patients 1192.1. Statistical analysis
The data were coded and computed on a statistical package for
social sciences SPSS version 11.5 for windows for statistical
analysis. Continuous variables were evaluated using t-test
and categorical variables using X2. Pearson correlation coefﬁ-
cient (r) test was done to examine strength and direction of
correlation between two variables. Correlation was weak if
r< 0.3, moderate if 0.3 < r< 0.6 and strong if r> 0.6. P va-
lue <0.05 was considered signiﬁcant.
3. Results
The population in our study had no signiﬁcant difference be-
tween the groups regarding male to female ratio, smoker/non
smoker, but group I showed a signiﬁcantly higher age than the
other groups, the demographic data are illustrated in Table 1.
Patients in group I had cardiovascular complications; 12
patients had ischemic heart disease13 (acute myocardial infarc-
tion, non ST segment elevation myocardial infarction, and
unstable angina), two patients with pulmonary hypertension,
one patient with pulmonary embolism, and ﬁve patients with
cerebrovascular disease.
Hypertensive patients had a signiﬁcant higher systolic and
diastolic blood pressures compared to control group IV
( Table 2). Both the systolic and diastolic blood pressures
had a signiﬁcant positive correlation with ADMA, while with
NO there was a signiﬁcant negative correlation r = 0.9
(P= 0.012; Tables 2 and 4 and Figs. 1 and 2).
Cardiovascular hypertensive groups I, II and III compared
to control group (group IV) showed a statistically signiﬁcant
increase in mean FBS and PPBs (P< 0.002 and 0.001, respec-
tively). Correlation coefﬁcient shows a strong positiveTable 1 Patients demography in all studied groups.
Group Group I Group II
Age (y)
Range 29–75* 24–70
Mean ± SD 52.2 ± 2.5 50.6 ± 2.4
Sex
Male 13 (65%) 12 (60%)
Female 7 (35%) 8 (40%)
Smoking 17 (85%) 14 (70%)
Diabetes mellitus 18 (90%) 19 (95%)
Dyslipidemia 20 (100%) 20 (100%)
Renal Impairment 20 (100%) 20 (100%)
* Means signiﬁcant to other groups.
Table 2 Systolic and diastolic blood pressures in all studied patien
Group I
(mean ± SD and range)
Group II
(mean ± SD and range)
G
(
SBP 176.85 ± 2.41A 153.45 ± 1.61A 1
160–195 140–165 1
DBP 102.35 ± 1.01A 95.01 ± 0.67A 8
95–110 90–100 8
SBP, systolic blood pressure; DBP, diastolic blood pressure.
A Means that group is signiﬁcant to control group.correlation between FBS and ADMA r= 0.9 (P= 0.002)
and strong negative correlation between FBS and NO,
r= 0.9 (P= 0.003). While PPBS had positive and negative
correlations with ADMA and NO, but it was not signiﬁcant
(P= 0.055 and 0.059, respectively, Tables 3 and 4).
There was a signiﬁcant increase in the mean urea and creat-
inine value in cardiovascular hypertensive groups I and II
compared to group III and control group P value <0.001
and 0.024, respectively. Even in hypertensive patients with
cardiovascular complications (group I), urea and creatinine
were highly signiﬁcant compared to group II (patients withGroup III Group IV (Control group) P value
37–70 35–65 0.0001
47.5 ± 2.02 45 ± 2.2
17 (85%) 6 (60%) 0.18
3 (15%) 4 (40%)
12 (60%) 3 (30%) 0.08
20 (100%) 0 (0%) 0.1
20 (100%) 4 (40%) 0.15
16 (80%) 0 (0%) 0.12
ts groups.
roup III
mean ± SD and range)
Control group
(mean ± SD and range)
P value
30.95 ± 0.99A 117.51 ± 1.66 0.011
20–135 110–125
5.35 ± 0.53A 78.31 ± 1.52 0.011
0–90 70–85
Figure 2 Correlation coefﬁcient between serum NO and blood
pressure in all studied patients groups.
120 O. Tayeh et al.uncontrolled hypertension without cardiovascular complica-
tions). Correlation coefﬁcient shows a strong positive correla-
tion between urea, creatinine and ADMA r= 0.99 and 0.9
(P= 0.001 and 0.002, respectively) and negative correlation
between urea, creatinine and NO r= 0.99 and 0.9
(P= 0.002 and 0.0018, respectively, Tables 3 and 4).
Cholesterol and triglycerides levels show signiﬁcant higher
level in group I (hypertensive patients with cardiovascular
complications), compared to other hypertensive groups I, II,
and control group. Also groups II and III show a higher signif-
icant cholesterol and triglyceride level in relation to control
group. Correlation coefﬁcient revealed a signiﬁcant positiveTable 3 Laboratory results for all studied patients groups and con
Group I
(mean ± SD and range)
Group II
(mean ± SD and range)
FBS 120.9 ± 42.00B
73.98–210.11
105.1 ± 25.00A
80.7–190.11
PPBS 171.4 ± 71.00B
108.11–334.16
143.64 ± 37.00A
110.3–277.15
Urea 122.55 ± 4.17*
90–150
72.8 ± 1.02*
65–80
Creatinine 2.13 ± 0.05*
1.8–2.5
1.75 ± 0.04*
1.5–2
Cholesterol 404.31 ± 7.98*
350–470
333.01 ± 6.04A
290–375
Triglyceride 282.75 ± 5.03*
250–320
209.31 ± 2.72A
190–230
NO 11.65 ± 0.75B
6–18
30.91 ± 1.31B
20–40
ADMA 2.29 ± 0.06B
1.9–2.7
1.41 ± 0.06B
1–1.8
Normal range: FBS and PPBS, fasting and postprandial blood sugar (up
(0.6–1.2 mg/dL), cholesterol (up to 200 mg/dL), triglyceride (up to 200 m
* Means signiﬁcant to all other groups.
A Means that group is signiﬁcant to control group.
B Means that group is signiﬁcant to group III and control group.correlation with ADMA and a signiﬁcant negative correlation
with NO (Tables 3 and 4 and Figs. 3 and 4).
ADMA levels was signiﬁcantly higher in the hypertensive
patients (groups I, II, and III) in relation to control group,
even hypertensive complicated cardiovascular group and pa-
tients who have uncontrolled hypertension (groups I and II)
had a signiﬁcant higher level of ADMA more than patients
with controlled hypertension (group III; Table 3 and Fig. 5).
The correlation between plasma ADMA and age in all studied
patients groups revealed a strong positive correlation
r= 0.904 (P< 0.049; Fig. 6). While Fig. 7 illustrated the cor-
relation coefﬁcient between age and NO levels in the study
population, which revealed a strong negative correlation
r= 0.927 (P< 0.037).
NO levels were signiﬁcantly lower in the hypertensive pa-
tients (groups I, II, and III) in relation to control group, while
hypertensive complicated cardiovascular group and patients
who have uncontrolled hypertension (groups I and II) had a
signiﬁcant lower level of NO more than patients with con-
trolled hypertension (group III; Table 3 and Fig. 5). There
was a strong inverse and signiﬁcant correlation between NO
and ADMA levels in the whole population (r= 0.9 and P
value 0.001) as shown in Fig. 8.
By correlation of the laboratory tests done in our study and
ADMA and NO levels; there were signiﬁcant positive correla-
tions between ADMA and all variables that serve as cardiovas-
cular risk factors (blood sugar, cholesterol, and triglyceride)
and on the other hand there were signiﬁcant negative correla-
tions between these risk factors and NO as shown in Table 4.
4. Discussion
Hypertension remains a common and serious problem, con-
tributing in a major way to the most common causes of mor-
bidity and mortality worldwide. Moreover, the main burdenstrol group.
Group III
(mean ± SD and range)
Control group
(mean ± SD and range)
P value
99.6 ± 26.4A
75–187
87.11 ± 10.41
74.91–105.12
0.002
137.00 ± 27.06A
118.2–223.1
85.32 ± 13.17
70.33–110.33
0.001
54.75 ± 1.52
43–65
28.9 ± 2.16
19–38
0.001
1.4 ± 0.03
1.2–1.6
0.91 ± 0.06
0.6–1.2
0.024
266.31 ± 3.53A
240–290
194.11 ± 11.13
145–245
0.018
174.91 ± 3.67A
150–200
95.41 ± 7.13
60–125
0.011
40.01 ± 0.67A
35–45
52.11 ± 1.43
45–60
0.001
1.11 ± 0.05A
0.8–1.5
0.55 ± 0.05
0.3–0.8
0.001
to 110 and 126 mg/dL, respectivelly), urea (10–50 mg/dL), creatinine
g/dL), ADMA (0.4–0.8 lmol/L); NO, nitric oxide (35–55 lmol/L).
Table 4 Correlations between ADMA and NO and other
laboratory results, blood pressure, and age.
ADMA NO
r P value r P value
FBS 0.9 0.002 0.9 0.003
PPBS 0.89 0.055 0.85 0.059
Urea 0.99 0.001 0.99 0.002
Creatinine 0.9 0.002 0.9 0.018
Cholesterol 0.9 0.018 0.9 0.011
Triglyceride 0.9 0.011 0.9 0.011
NO 0.9 0.001
ADMA 0.9 0.001
SBP 0.9 0.011 0.9 0.012
DBP 0.9 0.011 0.9 0.012
AGE 0.9 0.049 0.9 0.037
Figure 3 Correlation coefﬁcient between plasma ADMA and
serum Cholesterol in all studied patients groups.
Figure 4 Correlation coefﬁcient between serum NO and serum
cholesterol in all studied patients groups.
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Figure 5 ADMA and NO in the four patients groups.
Asymmetric dimethylarginine as a prognostic marker for cardiovascular complications in hypertensive patients 121associated with hypertension occur not in the relatively few
with severe disease but in the masses of patients with blood
pressure (BP) that are only minimally elevated.14,15
The main ﬁndings in this study were: ADMA – endogenous
inhibitor of eNOS – is signiﬁcantly high in all hypertensive
patients, while NO was signiﬁcantly low in all hypertensive
patient groups in comparison to control group. ADMA had
a signiﬁcant negative correlation to endothelial function as
measured by low serum NO. High plasma ADMA concentra-
tion was observed and signiﬁcantly correlated positively with
traditional cardiovascular risk factors, e.g., dyslipidemia, dia-
betes mellitus, and hypertension. While low serum NO, which
induces endothelial dysfunction was negatively correlated with
these traditional cardiovascular risk factors (P 6 0.05).
Matsuguma et al.16 reported that the plasma level of ADMA
was correlated with blood pressure levels, which is in agreement
with our study results, as ADMA was high in all hypertensive
patients in comparison to control group with a signiﬁcant
positive correlation with systolic and diastolic blood pressures
r= 0.977 (P= 0.011). However, Fliser et al.17 and Schulze etal.18 showed no correlation between ADMA and blood pres-
sure. While, Bakris et al.,19 Dayoub et al.,20 and Jacobi
et al.21 demonstrated that several factors such as age, insulin
resistance, and dyslipidemia could affect the plasma levels of
ADMA and they noted that these confounding factors and/or
cardiac medications might attenuate the positive correlation
between plasma ADMA levels and blood pressure, which could
explain the negative clinical studies. But the age of the patients
and hypercholesterolemia in our study were signiﬁcantly
Figure 6 Correlation coefﬁcient between plasma ADMA and
age in all studied patients groups.
Figure 7 Correlation coefﬁcient between serum NO and age in
all studied patients groups.
Figure 8 Correlation coefﬁcient between serum NO and ADMA
in all studied patients groups.
122 O. Tayeh et al.positively correlated with serum level of ADMA and also had a
negative signiﬁcant correlation with the serum level of NO.
The cause of high plasma ADMA concentration in essential
hypertension is presently unknown. Increased shear stress may
trigger ADMA synthesis, and high ADMA in hypertension
may therefore be an epiphenomenon of high BP.22 Alterna-
tively, high ADMAmay result from reduced catabolic rate sec-
ondary to DDAH inhibition brought about by oxidative
stress, a well-known feature of human hypertension.23
In patients with coronary atherosclerosis, endothelial
vasodilatory dysfunction is not conﬁned only to the epicardial
conductance vessels but also extends to the coronary resistance
vessels and microcirculation. Excessive inactivation of NO due
to increased oxidative stress occurs in smokers, diabetics andin hypercholesterolemia. At any level of total and LDL choles-
terol, the small dense LDL particle is the main culprit, which is
easily prone to lipid peroxidation and thereby adheres to the
endothelium.24 This can explain what we found in our study
that hypercholesterolemia was signiﬁcantly higher in group I
(hypertensive patients with cardiovascular complications)
more than the other groups. Also FBS and PPBS were signif-
icantly high in groups I and II (patients with complicated
hypertension and uncontrolled BP) in comparison to group
III (controlled BP) and control group. So high signiﬁcant lev-
els of serum cholesterol, FBS, and PPBS could be a reason for
the signiﬁcant reduction of the level of serum NO in the groups
I and II.
In our study; ADMA showed a signiﬁcant correlation with
blood glucose level and there were similar ﬁndings from animal
models and clinical studies that lead to the suggestion that
hyperglycemia may increase plasma ADMA levels concomi-
tantly with reduced ADMA metabolism by DDAH. However,
they leave open the question of whether glucose itself or rather
insulin is the agent that affects DDAH activity. In cultured
endothelial cells hyperglycemia-induced oxidative stress was
associated with reduced DDAH activity, resulting in elevated
ADMA concentrations in conditioned media and reduced
NO formation.25
Diminished NO bioactivity may cause constriction of coro-
nary arteries during exercise or during mental stress and
contribute to provocation of myocardial ischemia in patients
with coronary artery disease. Additionally, diminished nitric
oxide bioactivity may facilitate vascular inﬂammation that
could lead to oxidation of lipoproteins and foam cell forma-
tion, the precursor of the atherosclerotic plaque. Accordingly,
there is a causal relationship between improved endothelial
function and reduction in myocardial ischemia and acute cor-
onary events,26,27 and this was proved in our study, as the low-
est signiﬁcant serum level of NO was present in group I
(patients with complicated hypertension) to the control group.
Heibashy and Abdel Moniem28 reported that; the endothe-
lial dysfunction in hypercholesterolemic individuals could be
Asymmetric dimethylarginine as a prognostic marker for cardiovascular complications in hypertensive patients 123related to plasma concentration of ADMA, which is a strong
independent predictor of overall mortality and cardiovascular
outcome in hemodialysis patients, and increased plasma con-
centrations of ADMA have been reported in hypertension
and pre-eclampsia. It is increased early enough during athero-
genesis to be eligible as a causative factor;12 even small changes
in extracellular ﬂuid have been shown to correspond to large
enough changes in intracellular ADMA concentration that
can affect NOS activity.18 A study in healthy volunteers dem-
onstrated that intravenous ADMA infusion at a dose resulting
in pathophysiological concentrations augments peripheral and
renovascular resistance and arterial pressure.29 This led to sug-
gestion that; displacing ADMA with excess L-arginine30 could
be useful in hypertension, pre-eclampsia, and coronary heart
disease. Boger et al.31 and Bo¨ger and Ron32 stated that in off-
spring of patients with essential hypertension in whom endo-
thelial dysfunction is present, could be reverted to normal by
intra-brachial L-arginine. These results suggest that impair-
ment in eNO production precedes the onset of hypertension
that could be due to increase in the levels of ADMA. Also high
plasma ADMA concentration was observed in the presence of
hyperhomocysteinemia,33 inducing endothelial dysfunction in
some of these conditions.34
Patients in groups I and II show signiﬁcant high urea and
creatinine in comparison to controlled hypertensive patients
and control volunteer group. Urea and creatinine were posi-
tively correlated with serum ADMA level and this can be ex-
plained by Asagami et al.,35 Achan et al.,36 and Kielstein
et al.37 where they stated that; elevated ADMA in the context
of renal insufﬁciency occurs in a variety of ways, probably be-
cause the DDAH activity – which causes metabolic degrada-
tion to ADMA – is affected. Zoccali et al.38 demonstrated an
analysis of a large group of patients with end-stage renal fail-
ure that showed an inverse relationship between ADMA levels
and left ventricular (LV) ejection in a multivariate analysis.
ADMA was shown to be an independent and strong predictor
of LV ejection fraction. These ﬁndings raise the possibility that
a causal relationship between ADMA and LV dysfunction
may exist.
Cooke39 reported that; traditional cardiovascular risk fac-
tors impair endothelial vasodilator function by causing the
accumulation of ADMA. Furthermore, by blocking NO gen-
eration, ADMA initiates and promotes processes involved in
atherogenesis, plaque progression, and plaque rupture. So,
ADMA should be as a marker, which is a biochemical factor
mediating the adverse vascular effects of many other risk fac-
tors and markers. Also Makino et al.40 stated that; ADMA
may emerge as a prognostic marker positively associated with
risk like in other atherosclerotic vascular diseases. This could
be caused by changes in the relative contribution of other tra-
ditional cardiovascular risk factors, ADMA, and oxidative
stress to the progression of vascular diseases.
In conclusion, ADMA is elevated in hypertensive patients.
Elevated ADMA concentrations are associated with impaired
endothelium functions, which are demonstrated by NO reduc-
tion in the sera of hypertensive patients. ADMA is correlated
positively with the traditional cardiovascular risk factors. Also
there was a strong signiﬁcant negative correlation between NO
and ADMA levels in the whole hypertensive groups.References
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